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Gadolinium leakage into subarachnoid space and cystic metastases




Subarachnoid space (SAS) and cystic metastatic lesions of 
brain parenchyma appear hypointense on fluid-attenuated 
inversion-recovery (FLAIR) and T1-weighted magnetic reso-
nance imaging (MRI) unless there is a hemorrhage or ele-
vated protein content. Otherwise, delayed enhancement and 
accumulation of contrast media in SAS or cyst of metastases 
should be considered. We present hyperintense SAS and cys-
tic brain metastases of lung cancer on FLAIR and T1-weight-
ed MRI, respectively, in a patient who had been previously 
given contrast media for imaging of spinal metastases and 
had mildly impaired renal functions, and discuss the relevant 
literature. 
G adolinium (Gd) enhanced magnetic resonance imaging (MRI) is routinely performed for diagnosis and monitoring of various cen-tral nervous system diseases. On noncontrast T1-weighted imaging, 
most lesions are hypointense in the absence of blood products and diverse 
paramagnetic substances, fat or elevated protein content. Blood-brain bar-
rier (BBB) damage and the related leakage of contrast media into the extra-
cellular space from the vascular system result in abnormal enhancement 
following intravenous administration of Gd-based paramagnetic contrast 
materials. Therefore, numerous lesions of infectious, inflammatory, de-
myelinating, and malignant diseases are enhanced after contrast medium 
administration in the brain parenchyma (1). Gd accumulation within the 
cystic fluid of metastases causing a potential diagnostic misunderstanding 
has not been reported in the literature, to our knowledge.
On normal fluid-attenuated inversion-recovery (FLAIR) imaging, 
the inversion-recovery pulse nulls the signal from subarachnoid space 
(SAS), and it is hypointense unless there is accompanying blood, tu-
mor, inflammation or infection, as well as vascular engorgement. These 
conditions include subarachnoid hemorrhage, meningitis, meningeal 
carcinomatosis, leptomeningeal metastases, subacute infarct, subdural 
hematoma, adjacent neoplasms, dural venous thrombosis, and status 
epilepticus (2, 3). Rarely, oxygen supplementation during MRI and pre-
vious Gd-based contrast media administration may result in hyperin-
tense SAS. Gd accumulation in SAS may occur in patients with or with-
out renal insufficiency, and in conditions with or without BBB damage 
(2–5). Herein, we present a case with Gd leakage into SAS and cystic fluid 
of metastases with a brief review of the literature. 
Case report
A 48-year-old male with a metastatic lung cancer (squamous cell carci-
noma) was admitted to our hospital with complaints of lower back pain 
and lower limb weakness for 20 days. He had received his last chemother-
apy and radiotherapy treatment five months prior. On admission, neuro-
logical examination revealed lower limb paresis and paresthesia at T11–
L1 dermatomes, and the patient reported urine and fecal incontinence. 
In laboratory tests, blood urea concentration was 23.98 mg/dL (normal 
range, 6–20 mg/dL), blood creatinine concentration was 1.39 mg/dL (nor-
mal range, 0.7–1.2 mg/dL), and glomerular filtration rate (GFR) was 54.31 
mL/min/1.73 m² (estimated Modification of Diet in Renal Disease Formu-
la GFR, <60 mL/min/1.73 m²). Contrast enhanced whole spine MRI was 
performed using 0.01 mmol/kg gadopentetate dimeglumine for a suspect-
ed diagnosis of vertebral metastases and/or pathological fracture between 
T11 and L1 levels.
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MRI studies were performed on a 1.5 
Tesla MR scanner (Symphony, Tim Sys-
tems, Siemens Medical Systems, Erlan-
gen, Germany). Spine MRI demonstrat-
ed multiple bone metastases that were 
hypointense on precontrast T1-weight-
ed imaging (Fig. 1a) and enhanced on 
postcontrast images throughout the 
spine. There were also enhancing pial 
nodular metastases adjacent to the 
spinal cord and at the cauda equina 
on postcontrast T1-weighted imaging. 
Marked edema of the spinal cord was 
observed between C7 and T4 levels 
without a remarkable intramedullary 
enhancement. At the time of spinal im-
aging, because extensive spinal intradu-
ral extramedullary metastases and en-
hancing metastases in the cerebellum 
were detected (Fig. 1a), additional post-
contrast T1-weighted imaging of the 
brain was also obtained. It revealed lep-
tomeningeal carcinomatosis and cystic 
metastases in the right cerebral and left 
cerebellar hemispheres with a peripher-
al enhancement and hypointense cystic 
fluid (Fig. 1b). 
The patient was admitted to the medi-
cal oncology clinic with these findings. 
Approximately 24 hours after the first 
MRI, his physician, who was unaware 
of the postcontrast T1-weighted imag-
ing of the brain obtained during the 
spine imaging session, requested a new 
brain contrast-enhanced MRI. . At this 
second MRI, SAS was hypointense but 
the cystic metastatic lesions were hy-
perintense on precontrast T1-weighted 
imaging (Fig. 1c). Additionally, SAS 
was diffusely hyperintense (Fig. 2a) 
and cystic metastases were bright on 
FLAIR imaging. Following intravenous 
administration of same contrast media 
with the previous exam, leptomenin-
geal carcinomatosis and widespread 
parenchymal micronodular metasta-
ses were also observed. Together, the 
findings from both imaging sessions 
suggested leakage of Gd from the vas-
cular system into the central cystic 
fluid of parenchymal metastases and 
SAS. Two additional separate MRI, in-
cluding T1-weighted imaging, FLAIR, 
and gradient echo (GRE) images, were 
performed to follow Gd clearance from 
cystic fluid of parenchymal metastases 
and SAS, and to rule out hemorrhage 
Figure 1. a–e. Sagittal T1-weighted imaging 
of the cervical spine (a) (TR/TE, 531/11 ms) 
and axial postcontrast T1-weighted imaging 
of the posterior fossa (b) (TR/TE, 506/12 ms) 
show a hypointense cystic metastasis (arrows) 
with peripheral wall enhancement in the left 
medial cerebellar hemisphere. At hour 24, 
axial precontrast T1-weighted imaging (c) 
shows hyperintensity of the cystic fluid caused 
by Gd leakage (arrows). At hour 36, follow-up 
T1-weighted (d) and gradient echo (e) (TR/
TE, 632/17 ms; flip angle, 20°) images show 
hypointense cystic fluid (d, white arrow) that 
was cleared from Gd and persistent nodular 
hyperintensity at the medial wall due to 
hemorrhage (d, e, black arrows). Note the 
hypointense bone metastasis  
(a, star), meningeal nodular and linear 
enhancement (b, arrowhead), and 
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that might have also caused T1 short-
ening. The scans were performed at ap-
proximately 36 and 160 hours after ad-
ministration of the contrast material. At 
36 hours, cystic fluids of the parenchy-
mal metastases were hypointense with 
continued enhancement at the periph-
ery of the cyst on T1-weighted imag-
ing (Fig. 1d) that may in part be due to 
hemorrhage observed on GRE imaging 
(Fig. 1e); SAS and cyst fluid, however, 
were still hyperintense on FLAIR imag-
ing (not shown). On GRE imaging, SAS 
had no evidence of susceptibility (Fig. 
2b). After 160 hours, SAS and cyst flu-
id were cleared of Gd on FLAIR images 
(Fig. 2c), but subtle T1 hyperintensity at 
the periphery of the cyst remained on 
T1-weighted imaging images. 
The total dose of Gd given to the pa-
tient in the two scanning sessions was 30 
mL (gadopentetate dimeglumine, 0.01 
mmol/kg). During the hospital stay, re-
nal function parameters of the patient 
were mildly impaired.  
Discussion 
Increased signal intensity in the 
SAS has been described in numerous 
pathologic changes of the meninges 
and brain tissue on FLAIR imaging, 
including subarachnoid hemorrhage, 
meningitis, meningeal carcinomatosis, 
leptomeningeal metastases, subacute 
infarct, subdural hematoma, adjacent 
neoplasms, dural venous thrombosis, 
and status epilepticus (2, 3). Addition-
ally, supplemental oxygen during MRI 
and previous contrast media adminis-
tration can also cause artifactual SAS 
hyperintensity (1, 4–6). According to 
Braga et al. (7), supplemental oxygen 
at 100% is a main cause of artifactual 
SAS hyperintensity on FLAIR imaging, 
regardless of the anesthetic drug used. 
This artifact does not develop when 
50% oxygen is administered. Another 
cause for artifactual SAS hyperintensi-
ty is previous contrast media adminis-
tration. In a large series of 33 patients, 
Bozzao et al. (8) demonstrated hyper-
intense SAS on FLAIR imaging due to 
Gd leakage in 2–24 hours following Gd 
administration in pathologic condi-
tions with BBB disruption and neovas-
cularization. 
Although BBB disruption and neo-
vascularization result in leakage of 
contrast media into the extracellular 
space from vascular system, there is 
no evidence from a histopatholog-
ic study showing that damaged pial 
vessels could allow leakage of Gd into 
the SAS. The exact mechanism of lep-
tomeningeal and SAS enhancement re-
mains unclear (1, 8). Notably, Morris 
and Miller (3) showed that presence 
of abnormalities known to disrupt the 
BBB and renal insufficiency are not 
mandatory for SAS hyperintensity on 
FLAIR caused by previous Gd admin-
istration. Their findings also suggested 
that Gd chelates might move across an 
osmotic gradient at the circumventric-
ular organs with elevated plasma con-
centrations where there is no BBB, as 
in normal dura mater. An in vitro and 
animal model study by Mamourian et 
al. (9) with healthy dogs also showed 
that intravenously administered Gd 
could cross into the SAS in sufficient 
concentrations to alter the appearance 
of the SAS on FLAIR. They emphasized 
that SAS concentrations of Gd were 
proportional to the administered Gd 
dose, and that a dose three times high-
er than standard amounts (0.03 mmol/
kg) was essential to produce detectable 
changes (9). Therefore, signal changes 
related to leakage of Gd into SAS re-
quire sufficient Gd concentration in 
the plasma and/or BBB disruption or 
neovascularization. 
Not only is the total dose adminis-
tered to the patient important in af-
fecting the detection of Gd in the SAS 
and persistence of the hyperintensity 
on images, but also the persistence of 
Gd in plasma caused by renal func-
tional impairment plays a role (10). 
Gd chelates are cleared from plasma 
via glomerular filtration, with a nor-
mal plasma half-life of 1.6 hours. In 
patients with renal insufficiency, the 
plasma half-life of Gd chelates may 
be prolonged up to 30 hours (11, 12). 
Hence, either renal insufficiency or an 
overdose administered to patients may 
be responsible for hyperintense SAS on 
FLAIR imaging. 
In our patient, resolution of cystic flu-
id hyperintensity on T1-weighted imag-
es occurred at 36 hours, and both cystic 
fluid and SAS hyperintensity on FLAIR 
images was observed at 160 hours. In 
the literature, resolution of the hy-
perintensity on FLAIR or T1-weighted 
images, which developed following ad-
ministration of gadopentetate dimeglu-
mine and gadodiamide (5, 8, 9) ranged 
Figure 2. a–c. Axial FLAIR (TR/TE/TI, 8000/127/2183 ms) image at hour 24 (a) shows diffuse SAS hyperintensity due to Gd leakage. On the gradient 
echo image (b), there is no evidence of hemorrhage. At hour 160, the follow-up FLAIR image (c) shows hypointense SAS with total clearance from Gd. 
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between 48 hours to two weeks (3, 
8-10). Although Bozzao et al. (8) stat-
ed that resorption time of Gd from SAS 
is 48 hours on FLAIR, no other study 
has investigated the exact resolution 
time of hyperintensity in varying con-
ditions, including total dose or renal 
function degree. In the current patient, 
BBB disruption and abnormal plasma 
clearance due to mild renal function-
al impairment might have resulted in 
accumulation of Gd in cystic metasta-
ses, and SAS on T1-weighted and FLAIR 
images. Two administrations of Gd (15 
cc each, for a total of 30 cc) within ap-
proximately 30 hours also might have 
prolonged the clearance of the Gd from 
the plasma and resulted in continued 
hyperintensity up to the 160 hours on 
FLAIR images. 
In our patient, SAS hyperintensi-
ty on FLAIR could not be attributed 
to subarachnoid hemorrhage, as evi-
denced from GRE. However, the cystic 
metastasis located in the left medial 
cerebellar hemisphere had micronodu-
lar and peripheral susceptibility due to 
blood, and this may explain the lack of 
apparent signal alteration in the lesion 
wall on T1-weighted images from 36 to 
160 hours. Still, the cystic fluid did not 
show hemorrhage on GRE, supporting 
our Gd-leakage hypothesis. 
We also observed hyperintense cys-
tic metastases on T1-weighted images 
caused by previous Gd administration. 
Breast cancer, adenocarcinoma of lung 
cancer, thymic squamous cell carcino-
ma metastases can be cystic/necrotic 
(13). Abnormally proliferating vessels 
of high-grade tumors have intercellu-
lar gaps and discontinuous basement 
membrane, causing both intravascular 
(flow related) and interstitial (perme-
ability related) enhancement (1). Boz-
zao et al. (8) showed FLAIR hyperin-
tensity of cystic cavities in a necrotic 
brain mass and a surgical cavity due to 
Gd leakage. Given that FLAIR is much 
more sensitive to changes in Gd con-
centration (9), we further demonstrat-
ed this finding on T1-weighted imag-
ing. 
In conclusion, radiologists should 
be aware of delayed or persistent Gd 
enhancement that can occur in cysts 
of the metastases (and possibly of 
other necrotic tumors), and SAS on 
T1-weighted and FLAIR imaging. In 
such situations, radiologists should 
check history of previous Gd admin-
istration in the patients, especially in 
those without renal impairment.  
Conflict of interest disclosure
The authors declared no conflicts of interest. 
References
1. Smirniotopoulos JG, Murphy FM, Rushing 
EJ, Rees JH, Schroeder JW. Patterns of con-
trast enhancement in the brain and me-
ninges. Radiographics 2007; 27:525–551. 
[CrossRef]
2. Maeda M, Yagishita A, Yamamoto T, Saku-
ma H, Takeda K. Abnormal hyperintensity 
within the subarachnoid space evaluated 
by fluid-attenuated inversion-recovery MR 
imaging: a spectrum of central nervous sys-
tem diseases. Eur Radiol 2003; 13:192–201. 
[CrossRef]
3. Morris JM, Miller GM. Increased signal in 
the subarachnoid space on fluid-attenuated 
inversion recovery imaging associated with 
the clearance dynamics of gadolinium che-
late: a potential diagnostic pitfall. AJNR Am J 
Neuroradiol 2007; 28:1964–1967. [CrossRef]
4. Deliganis AV, Fisher DJ, Lam AM, Maravil-
la KR. Cerebrospinal fluid signal intensity 
increase on FLAIR MR images in patients 
under general anesthesia: the role of supple-
mental O2. Radiology 2001; 218:152–156.
5. Zatman P, Hourihan MD. Contrast enhance-
ment of cerebrospinal fluid on delayed MRI 
in a patient with an epidural abscess and re-
nal failure. Br J Radiol 2002; 75:474–477.
6. Stuckey SL, Goh TD, Heffernan T, Rowan D. 
Hyperintensity in the subarachnoid space 
on FLAIR MRI. AJR Am J Roentgenol 2007; 
189:913–921. [CrossRef]
7. Braga FT, da Rocha AJ, Hernandez Filho G, 
Arikawa RK, Ribeiro IM, Fonseca RB. Rela-
tionship between the concentration of sup-
plemental oxygen and signal intensity of 
CSF depicted by fluid-attenuated inversion 
recovery imaging. AJNR Am J Neuroradiol 
2003; 24:1863–1868.
8. Bozzao A, Floris R, Fasoli F, Fantozzi LM, Col-
onnese C, Simonetti G. Cerebrospinal fluid 
changes after intravenous injection of gad-
olinium chelate: assessment by FLAIR MR 
imaging. Eur Radiol 2003; 13:592–597. 
9. Mamourian AC, Hoopes PJ, Lewis LD. Visu-
alization of intravenously administered con-
trast material in the CSF on fluid-attenuated 
inversion-recovery MR images: an in vitro 
and animal-model investigation. AJNR Am 
J Neuroradiol 2000; 21:105–111.
10. Rai AT, Hogg JP. Persistence of gadolinium 
in CSF: a diagnostic pitfall in patients with 
end-stage renal disease. AJNR Am J Neurora-
diol 2001; 22:1357–1361.
11. Joffe P, Thomsen HS, Meusel M. Pharmaco-
kinetics of gadodiamide injection in patients 
with severe renal insufficiency and patients 
undergoing hemodialysis or continous am-
bulatory peritoneal dialysis. Acad Radiol 
1998; 5:491–502. [CrossRef]
12. Shellock FG, Kanal E. Safety of magnetic 
resonance imaging contrast agents. J Magn 
Reson Imaging 1999; 10:477–484. [CrossRef]
13. Troiani C, Lopes CC, Scardovelli CA, Nai 
GA. Cystic brain metastases radiologically 
simulating neurocysticercosis. Sao Paulo 
Med J 2011; 129:352–356. [CrossRef]
